KRAS and pancreatic neoplasm: In view of the therapeutic relevance of these fusions and the overall high incidence of oncogenic fusions in KRAS wild-type pancreatic tumors, we recommend systematic testing of the KRAS mutation status and screening for gene fusions in the absence of KRAS mutations.